<DOC>
	<DOCNO>NCT02704767</DOCNO>
	<brief_summary>Tarceva establish first-line therapy advance lung adenocarcinoma mutant EGFR patients.However , benefit last 6-8 months.So consider add apatinib , tyrosine kinase inhibitor VEGF , therapy patient .</brief_summary>
	<brief_title>Tarceva With Without Apatinib Advanced Lung Adenocarcinoma</brief_title>
	<detailed_description>Lung adenocarcinoma common NSCLC , patient diagnose advanced stage.The first-line therapy include chemotherapy target therapy .Tarceva establish first-line therapy advance lung adenocarcinoma mutant EGFR patients.However , benefit last 6-8 months.So consider add apatinib , tyrosine kinase inhibitor VEGF , therapy patients.We design study find whether addition apatinib Tarceva would enhance efficacy Tarceva .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>lung adenocarcinoma prove histology ; mutant EGFR ; ECOG PS 02 ; Clinical stage IIIb IV ; without fatal disease ; without hemorrhagic disease ; normal liver , renal bone marrow function , pregnant . ECOG PS 35 ; abnormal liver , renal bone marrow function , pregnant ; severe disease ; wild type EGFR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>